Candida infections account for 80% of all fungal infections in the hospital environment, including bloodstream, urinary tract and surgical site infections. Bloodstream infections are now a major challenge for tertiary hospitals worldwide due to their high prevalence and mortality rates. The incidence of candidemia in tertiary public hospitals in Brazil is approximately 2.5 cases per 1000 hospital admissions. Due to the importance of this infection, the authors provide a review of the diversity of the genus Candida and its clinical relevance, the therapeutic options and discuss the treatment of major infections caused by Candida. Each topography is discussed with regard to epidemiological, clinical and laboratory diagnostic and therapeutic recommendations based on levels of evidence. © 2013 Elsevier Editora Ltda.173283312Colombo, A.L., Guimarães, T., Epidemiology of hematogenous infections due to Candida spp. (2003) Rev Soc Bras Med Trop, 36, pp. 599-607Dignani, M.C., Solomkin, J.S., Anaissie, E., Candida (2003) Medical mycology. 1, pp. 195-239. , Churchill Livingstone, Filadélfia, E. Anaissie, M.R. McGinnis, M.A. Pfaller (Eds.)Vanden Abbeele, A., de Meel, H., Ahariz, M., Perraudin, J.P., Beyer, I., Courtois, P., Denture contamination by yeasts in the elderly (2008) Gerodontology, 25, pp. 222-228Johnson, N.W., The mouth in HIV/AIDS: markers of disease status and management challenges for the dental profession (2010) Aust Dent J, 55 (SUPPL. 1), pp. 85-102Kennedy, M.A., Sobel, J.D., Vulvovaginal candidiasis caused by non-albicans Candida species: new insights (2010) Curr Infect Dis Rep, 12, pp. 465-470Achkar, J.M., Fries, B.C., Candida infections of the genitourinary tract (2010) Clin Microbiol Rev, 23, pp. 253-273Morace, G., Borghi, E., Fungal infections in ICU patients: epidemiology and the role of diagnostics (2010) Minerva Anestesiol, 76, pp. 950-956Wey, S.B., Mori, M., Pfaller, M.A., Woolson, R.F., Wenzel, R.P., Hospital acquired candidemia: the attributable mortality and excess length of stay (1988) Ann Intern Med, 148, pp. 2642-2645Colombo, A.L., Nucci, M., Park, B.J., Epidemiology of candidemia in Brazil: a nationwide sentinel surveillance of candidemia in eleven medical centers (2006) J Clin Microbiol, 44, pp. 2816-2823Bassetti, M., Trecarichi, E.M., Righi, E., Incidence, risk factors and predictors of outcome of candidemia: survey in 2 Italian university hospitals (2007) Diagn Microbiol Infect Dis, 58, pp. 325-331Diekema, D.J., Messer, S.A., Brueggemann, A.B., Epidemiology of candidemia: 3-year results from the emerging infections and the epidemiology of Iowa organisms study (2002) J Clin Microbiol, 40, pp. 1298-1302Thom, K., Forrest, G., Gastrointestinal infections in immunocompromised hosts (2006) Curr Opin Gastroenterol, 22, pp. 18-23Pappas, P.G., Kauffman, C.A., Andes, D., Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America (2009) Clin Infect Dis, 48, pp. 503-535Barbaro, G., Barbarini, G., Di Lorenzo, G., Fluconazole compared with itraconazole in the treatment of esophageal candidiasis in AIDS patients: a double-blind, randomized, controlled clinical study (1995) Scand J Infect Dis, 27, pp. 613-617Queiroz-Telles, F., Silva, N., Carvalho, M.M., Evaluation of efficacy and safety of itraconazole oral solution for the treatment of oropharyngeal candidiasis in AIDS patients (2001) Braz J Infect Dis, 5, pp. 60-66Ally, R., Schurmann, D., Kreisel, W., A randomized, double blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients (2001) Clin Infect Dis, 33, pp. 1447-1454Vasquez, J.A., Skiest, D.J., Nieto, L., A multicenter randomized trial evaluating posaconazole versus fluconazole for the treatment of oropharyngeal candidiasis in subjects with HIV/AIDS (2006) Clin Infect Dis, 42, pp. 1179-1186Skiest, D.J., Vazquez, J.A., Anstead, G.M., Posaconazole for the treatment of azole refractory oropharyngeal and esophageal candidiasis in subjects with HIV infections (2007) Clin Infect Dis, 44, pp. 607-614Finlay, P.M., Richardson, M.D., Robertson, A.G., A comparative study of the efficacy of fluconazole and amphotericin B in the treatment of oropharyngeal candidosis in patients undergoing radiotherapy for head and neck tumours (1996) Br J Oral Maxillofac Surg, 34, pp. 23-25Villanueva, A., Gotuzzo, E., Arathoon, E.G., A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis (2002) Am J Med, 113, pp. 294-299Krause, D.S., Simjee, A.E., van Rensburg, C., A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis (2004) Clin Infect Dis, 39, pp. 770-775Colombo, A.L., Guimarães, T., Candiduria: a clinical and therapeutic approach (2007) Rev Soc Bras Med Trop, 40, pp. 332-337deWet, N., Llanos-Cuentas, A., Suleiman, J., A randomized, double blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV positive patients (2004) Clin Infect Dis, 39, pp. 842-849Giraldo, P., Witkin, S., Vaginal candidiasis: an incomprehensible challenge (1998) I Bras Dis Sex Transm, 10, pp. 31-36Holanda, A., Fernandes, A., Bezerra, C., Milan, E., Candidíase vulvovaginal: uma revisão de literatura (2005) Femina, 33, pp. 47-51Novawack, D., Lara, F., Estudo dos aspectos clínicos, epidemiológicos e atualização terapêutica das vulvovaginites por Candida sp, Trichomonas vaginalis e vaginoses bacterianas por Gardnerella vaginalis (1999) JBM, 77, pp. 46-50Galle, L., Gianinni, M., Prevalência e susceptibilidade de leveduras vaginais (2004) J Bras Patol Med Lab, 40, pp. 229-236Sobel, J.D., Pathogenesis and treatment of recurrent vulvovaginal candidiasis (1992) Clin Infect Dis, 14, pp. S148-S153Sobel, J.D., Vulvovaginal candidosis (2007) Lancet, 369, pp. 1961-1971Costa, M., Fernandes, O., Silva, M., Candidíase vulvovaginal: aspectos clínicos, tratamento oral com azólicos e suscetibilidade in vitro (2003) Rev Pat Trop, 32, pp. 145-162Watson, M.C., Grimshaw, J.M., Bond, C.M., Mollison, J., Ludbrook, A., Oral versus intra-vaginal imidazole and triazole anti-fungal agents for the treatment of uncomplicated vulvovaginal candidiasis (thrush): a systematic review (2002) BJOG, 109, pp. 85-95Urunsak, M., Ilkit, M., Euruke, C., Urunsak, I., Clinical and mycological efficacy of single-day oral treatment with itraconazole (400mg) in acute vulvovaginal candidosis (2004) Mycoses, 47, pp. 422-427Bennett, R.J., A Candida-based view of fungal sex and pathogenesis (2009) Genome Biol, 10, p. 230Kimberly, A.W., Stuart, M.B., Sexually transmitted diseases treatment guidelines 2006 (2006) MMWR, 55, pp. 1-54Sobel, J.D., Wiesenfeld, H.C., Martens, M., Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis (2004) N Engl J Med, 351, pp. 876-883Fong, I.W., The value of chronic suppressive therapy with itraconazole versus clotrimazole in women with recurrent vaginal candidiasis (1992) Genitourin Med, 68, pp. 374-377Witt, A., Kaufmann, U., Bitschnau, M., Monthly itraconazole versus classic homeopathy for the treatment of recurrent vulvovaginal candidiasis: a randomised trial (2009) BJOG, 116, pp. 1499-1505Ray, D., Goswami, R., Banerjee, U., Prevalence of Candida glabrata and its response to boric acid vaginal suppositories in comparison with oral fluconazole in patients with diabetes and vulvovaginal candidiasis (2007) Diabetes Care, 30, pp. 312-317Alvarez-Lerma, F., Nolla-Salas, J., Leon, C., Candiduria in critically ill patients admitted to intensive care medical units (2003) Intensive Care Med, 29, pp. 1069-1076Kauffman, C.A., Candiduria (2005) Clin Infect Dis, 41, pp. S371-S376Sobel, J.D., Fisher, J.F., Kauffman, C.A., Newman, C.A., Candida urinary tract infections - epidemiology (2011) Clin Infect Dis, 52 (SUPPL. 6), pp. S433-S436Nucci, M., Candiduria in hospitalized patients: a review (2000) Braz J Infect Dis, 4, pp. 168-172Oliveira, R.D., Maffei, C.M., Martinez, R., Nosocomial urinary tract infections by Candida species (2001) Rev Assoc Med Bras, 47, pp. 231-235Coleman, D.C., Rinaldi, M.G., Haynes, K.A., Importance of Candida species other than Candida albicans as opportunistic pathogens (1998) Med Mycol, 36 (SUPPL. 1), pp. 156-165Kobayashi, C.C., De Fernandes, O.F., Miranda, K.C., De Sousa, E.D., Silva Mdo, R., Candiduria in hospital patients: a study prospective (2004) Mycopathologia, 158, pp. 49-52Passos, X.S., Sales, W.S., Maciel, P.J., Candida colonization in intensive care unit patients' urine (2005) Mem Inst Oswaldo Cruz, 100, pp. 925-928Sobel, J.D., Controversies in the diagnosis of candiduria: what is the critical colony count (2002) Curr Treat Opt Infect Dis, 4, pp. 81-83Fisher, J.F., Newman, C.L., Sobel, J.D., Yeasts in the urine: solutions for a budding problem (1995) Clin Infect Dis, 20, pp. 183-189Ang, B.S.P., Telenti, A., King, B., Steckalberg, J.M., Wilson, W.D., Candidemia from urinary tract source: microbiological aspects and clinical significance (1993) Clin Infect Dis, 17, pp. 622-627Lundstrom, T., Sobel, J., Nosocomial candiduria: a review (2001) Clin Infect Dis, 32, pp. 1602-1607Sobel, J.D., Kauffman, C.A., McKinsey, D., Candiduria: a randomized, double-blind study of treatment with fluconazole and placebo (2000) Clin Infect Dis, 30, pp. 19-24Fan-Havard, P., O'Donovan, C., Smith, S.M., Oh, J., Bamberger, M., Eng, R.H.K., Oral fluconazole versus amphotericin B bladder irrigation for treatment of candidal funguria (1995) Clin Infect Dis, 21, pp. 960-965Fisher, J.F., Sobel, J.D., Kauffman, C.A., Newman, C.A., Candida urinary tract infections - treatment (2011) Clin Infect Dis, 52 (SUPPL. 6), pp. S457-S466Johnson, J.R., Should all catheterized patients with candiduria be treated? (1993) Clin Infect Dis, 17, p. 814Tavanti, A., Davidson, A.D., Gow, N.A., Maiden, M.C., Odds, F.C., Candida orthopsilosis and Candida metapsilosis spp. nov. to replace Candida parapsilosis groups II and III (2005) J Clin Microbiol, 43, pp. 284-292Bibashi, E., Memmos, D., Kokolina, E., Fungal peritonitis complicating peritoneal dialysis during an 11-year period: report of 46 cases (2003) Clin Infect Dis, 36, pp. 927-931Powe, N.R., Septicemia in dialysis patients: incidence, risk factors and prognosis (1999) Kidney Int, 55, pp. 1081-1090Chen, K.H., Chang, C.T., Yu, C.C., Candida parapsilosis peritonitis has more complications than other Candida peritonitis in peritoneal dialysis patients (2006) Ren Fail, 28, pp. 241-246Wang, A.Y., Yu, A.W., Li, P.K., Factors predicting outcome of fungal peritonitis in peritoneal dialysis: analysis of a 9-year experience of fungal peritonitis in a single center (2000) Am J Kidney Dis, 36, pp. 1183-1192Prasad, N., Gupta, A., Fungal peritonitis in peritoneal dialysis patients (2005) Perit Dial Int, 25, pp. 207-222Matuszkiewicz-Rowinska, J., Update on fungal peritonitis and its treatment (2009) Perit Dial Int, 29 (SUPPL. 2), pp. S161-S165Kameoka, H., Kumakawa, K., Matuoka, T., Nakano, M., Shiraiwa, Y., Yamaguchi, O., Intraperitoneal fluconazole for fungal peritonitis in CAPD: report of two cases (1999) Perit Dial Int, 19, pp. 481-483Wong, P.N., Lo, K.Y., Tong, G.M., Treatment of fungal peritonitis with a combination of intravenous amphotericin B and oral flucytosine and delayed catheter replacement in continuous ambulatory peritoneal dialysis (2008) Perit Dial Int, 28, pp. 155-162Cornely, O.A., Lasso, M., Betts, R., Caspofungin for the treatment of less common forms of invasive candidiasis (2007) J Antimicrob Chemother, 60, pp. 363-369Sandven, P., Qvist, H., Skovlund, E., Significance of Candida recovered from intraoperative specimens in patients with intra-abdominal perforations (2002) Crit Care Med, 30, pp. 541-547Gonçalves, S.S., Amorim, C.S., Nucci, M., Prevalence rates and antifungal susceptibility profiles of the Candida parapsilosis species complex: results from a nationwide surveillance of candidaemia in Brazil (2010) Clin Microbiol Infect, 16, pp. 885-887Calandra, T., Bille, J., Schneider, R., Mosimann, F., Francioli, P., Clinical significance of Candida isolated from peritoneum in surgical patients (1989) Lancet, 2, pp. 1437-1440Montravers, P., Dupont, H., Gauzit, R., Candida as a risk factor for mortality in peritonitis (2006) Crit Care Med, 34, pp. 646-652Solomkin, J.S., Mazuski, J.E., Bradley, J.S., Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America (2010) Clin Infect Dis, 50, pp. 133-164Stijn, I., Blota, B., Koenraad, H., Vandewoudea, B., Jan, J., Candida peritonitis (2007) Curr Opin Crit Care, 13, pp. 195-199Azoulay, E., Cohen, Y., Zahar, J.R., Practices in nonneutropenic ICU patients with Candida-positive airway specimens (2004) Intensive Care Med, 30, pp. 1384-1389Nunley, D.R., Gal, A.A., Vega, J.D., Perlino, C., Smith, P., Lawrence, E.C., Saprophytic fungal infections and complications involving the bronchial anastomosis following human lung transplantation (2002) Chest, 122, pp. 1185-1191El-Ebiary, M., Torres, A., Fabregas, N., Significance of the isolation of Candida species from respiratory samples in critically ill, non-neutropenic patients. An immediate postmortem histologic study (1997) Am J Respir Crit Care Med, 156, p. 583Alvarez-Lerma, F., Palomar, M., Leon, C., Fungal colonization and/or infection in intensive care units. Multicenter study of 1,562 patients (2003) Med Clin (Barc), 121, pp. 161-166Kontoyiannis, D.P., Reddy, B.T., Torres, H.A., Pulmonary candidiasis in patients with cancer: an autopsy study (2002) Clin Infect Dis, 34, pp. 400-403Franquet, T., Muller, N.L., Lee, K.S., Oikonomou, A., Flint, J.D., Pulmonary candidiasis after hematopoietic stem cell transplantation: thin-section CT findings (2005) Radiology, 236, pp. 332-337Hiller, E., Zavrel, M., Hauser, N., Adaptation, adhesion and invasion during interaction of Candida albicans with the host-focus on the function of cell wall proteins (2011) Int J Med Microbiol, 301, pp. 384-389Oner-Eyuboglu, F., Karacan, O., Akcay, S., Arslan, H., Demirhan, B., Haberal, M., Invasive pulmonary fungal infections in solid organ transplant recipients: a four-year review (2003) Transplant Proc, 35, pp. 2689-2691Yamada, H., Kotaki, H., Takahashi, T., Recommendations for the treatment of fungal pneumonias (2003) Expert Opin Pharmacother, 4, pp. 1241-1258Cole, G.T., Halawa, A.A., Anaisse, E.J., The role of the gastrointestinal tract in hematogenous candidiasis: from the laboratory to the bedside (1996) Clin Infect Dis, 22 (SUPPL. 2), pp. 73-88Alexander, J.W., Boyce, S.T., Babcock, G.F., The process of microbial translocation (1990) Ann Surg, 212, pp. 496-510Lunel, F.M.V., Meis, J.F.G.M., Voss, A., Nosocomial fungal infections: candidemia (1999) Diagn Microbiol Infect Dis, 34, pp. 213-220Wey, S.B., Mori, M., Pfaller, M.A., Woolson, R.F., Wenzel, R.P., Hospital acquired candidemia. The attributable mortality and excess length of stay (1988) Arch Intern Med, 148, pp. 2642-2645Colombo, A.L., Perfect, J., DiNubile, M., Global distribution and outcomes for Candida species causing invasive candidiasis: results from an international randomized double-blind study of caspofungin versus amphotericin B for the treatment of invasive candidiasis (2003) Eur J Clin Microbiol Infect Dis, 22, pp. 470-474Pasqualotto, A.C., Zimerman, R.A., Alves, S.H., Take control over your fluconazole prescriptions: the growing importance of Candida glabrata as an agent of candidemia in Brazil (2008) Infect Control Hosp Epidemiol, 29, pp. 898-899Debusk, C.H., Daoud, R., Thirumoorthi, M.C., Wilson, F.M., Khatib, R., Candidemia: current epidemiologic characteristics and a long term follow-up of the survivors (1994) Scand J Infect Dis, 26, pp. 697-703Kriengkauykiat, J., Ito, J.I., Dadwal, S.S., Epidemiology and treatment approaches in management of invasive fungal infections (2011) Clin Epidemiol, 3, pp. 175-191Ben-Ami, R., Garcia-Effron, G., Lewis, R.E., Fitness and virulence costs of Candida albicans FKS1 hot spot mutations associated with echinocandin resistance (2011) J Infect Dis, 204, pp. 626-635Bodey, G.P., Luna, M., Skin lesions associated with disseminated candidiasis (1974) JAMA, 229, pp. 1466-1468Rodriguez-Adrian, L.J., King, R.T., Tamayo-Derat, L.G., Miller, J.W., Garcia, C.A., Rex, J.H., Retinal lesions as clues to disseminated bacterial and candidal infections: frequency, natural history, and etiology (2003) Medicine (Baltimore), 82, pp. 187-202Oude Lashof, A.M., Rothova, A., Sobel, J.D., Ocular manifestations of candidemia (2011) Clin Infect Dis, 53, pp. 262-268Krishna, R., Amuh, D., Lowder, C.Y., Gordon, S.M., Adal, K.A., Hall, G., Should all patients with candidemia have an ophthalmic examination to rule out ocular candidiasis (2000) Eye, 14, pp. 30-34Filler, S.G., Kullberg, B.J., Deep-seated candidal infections (2003) Medical mycology, pp. 341-348. , Churchill Livingstone, Filadélfia, E. Anaissie, M.R. McGinnis, M.A. Pfaller (Eds.)Donnino, M.W., Goyal, N., Terlecki, T.M., Inadequate blood volume collected for culture: a survey of health care professionals (2007) Mayo Clin Proc, 82, pp. 1069-1072Horvath, L.L., George, B.J., Hospenthal, D.R., Detection of fifteen species of Candida in an automated blood culture system (2007) J Clin Microbiol, 45, pp. 3062-3064Masood, A., Sallah, S., Chronic disseminated candidiasis in patients with acute leukemia: emphasis on diagnostic definition and treatment (2005) Leuk Res, 29, pp. 493-501Almirante, B., Cuenca-Estrella, M., Candidemia: impact of epidemiological studies on the treatment and prognosis of a serious infection (2011) Enferm Infecc Microbiol Clin, 29, pp. 325-327Motta, A.L., Almeida, G.M., Almeida Júnior, J.N., Burattini, M.N., Rossi, F., Candidemia epidemiology and susceptibility profile in the largest Brazilian teaching hospital complex (2010) Braz J Infect Dis, 14, pp. 441-448Sanglard, D., Odds, F.C., Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences (2002) Lancet Infect Dis, 2, pp. 73-85Andes, D.R., Safdar, N., Baddley, J.W., (2012), 54, pp. 1110-1122. , for the Mycoses Study Group. Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials. Clin Infect DisRex, J.H., Pappas, P.G., Karchmer, A.W., A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects (2003) Clin Infect Dis, 36, pp. 1221-1228Bates, D.W., Su, L., Yu, D.T., Mortality and costs of acute renal failure assSullivan, D., Coleman, D., Candida dubliniensis: characteristics and identification (1998) J Clin Microbiol, 36, pp. 329-334Mariano, P.L., Milan, E.P., da Matta, D.A., Colombo, A.L., Candida dubliniensis identification in Brazilian yeast stock collection (2003) Mem Inst Oswaldo Cruz, 98, pp. 533-538Krcmery, V., Barnes, A.J., Non-albicans Candida spp. causing fungemia: pathogenicity and antifungal resistance (2002) J Hosp Infect, 50, pp. 243-260Godoy, P., Tiraboschi, I.N., Severo, L.C., Species distribution and antifungal susceptibility profile of Candida spp. bloodstream isolates from Latin American hospitals (2003) Mem Inst Oswaldo Cruz, 98, pp. 401-405Pfaller, M.A., Nosocomial candidiasis: emerging species, reservoirs and modes of transmission (1996) Clin Infect Dis, 22 (SUPPL. 2), pp. S89-S94Colombo, A.L., Guimarães, T., Silva, L.R., Prospective observational study of candidemia in São Paulo, Brazil: incidence rate, epidemiology, and predictors of mortality (2007) Infect Control Hosp Epidemiol, 28, pp. 570-576Costa, S.F., Marinho, I., Araújo, E.A., Manrique, A.E., Medeiros, E.A.S., Levin, A.S., Nosocomial fungaemia: a 2-year prospective study (2000) J Hosp Infect, 45, pp. 69-72Levin, A.S., Costa, S.F., Mussi, N.S., Candida parapsilosis fungemia associated with implantable and semiimplantable central venous catheters and the hands of health care workers (1998) Diagn Microbiol Infect Dis, 30, pp. 243-249Pfaller, M.A., Messer, S.A., Moet, G.J., Jones, R.N., Castanheira, M., Candida bloodstream infections: comparison of species distribution and resistance to echinocandin and azole antifungal agents in Intensive Care Unit (ICU) and non-ICU settings in the SENT RY Antimicrobial Surveillance Program (2008-2009) (2011) Int J Antimicrob Agents, 38, pp. 65-69Pfaller, M.A., Diekema, D.J., Ostrosky-Zeichner, L., Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interpretive MIC breakpoints (2008) J Clin Microbiol, 46, pp. 2620-2629Mora-Duarte, J., Betts, R., Rotstein, C., Comparison of caspofungin and amphotericin B for invasive candidiasis (2002) N Engl J Med, 347, pp. 2020-2029Kuse, E.R., Chetchotisakd, P., da Cunha, C.A., Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial (2007) Lancet, 369, pp. 1519-1527Reboli, A.C., Rotstein, C., Pappas, P.G., Anidulafungin versus fluconazole for invasive candidiasis (2007) N Engl J Med, 356, pp. 2472-2482Kofteridis, D.P., Lewis, R.E., Kontoyiannis, D.P., Caspofungin-nonsusceptible Candida isolates in cancer patients (2010) J Antimicrob Chemother, 65, pp. 293-295Colombo, A.L., Ngai, A.L., Bourque, M., Caspofungin use in patients with invasive candidiasis caused by common non-albicans Candida species: review of the caspofungin database (2010) Antimicrob Agents Chemother, 54, pp. 1864-1871Kale-Pradhan, P.B., Morgan, G., Wilhelm, S.M., Johnson, L.B., Comparative efficacy of echinocandins and nonechinocandins for the treatment of Candida parapsilosis infections: a meta-analysis (2010) Pharmacotherapy, 30, pp. 1207-1213Melo, A.S., Bizerra, F.C., Freymüller, E., Arthington-Skaggs, B.A., Colombo, A.L., Biofilm production and evaluation of antifungal susceptibility amongst clinical Candida spp. isolates, including strains of the Candida parapsilosis complex (2011) Med Mycol, 49, pp. 253-262Wingard, J.R., Importance of Candida species other than C. albicans as pathogens in oncology patients (1995) Clin Infect Dis, 20, pp. 115-125Colombo, A.L., Nucci, M., Salomão, R., High rate of nonalbicans candidemia in Brazilian tertiary care hospitals (1999) Diagn Microbiol Infect Dis, 34, pp. 281-286Goldani, L.Z., Mario, P.S., Candida tropicalis fungemia in a tertiary care hospital (2003) J Infect, 46, pp. 150-160Alp, S., Sancak, B., Hascelik, G., Arikan, S., Influence of different susceptibility testing methods and media on determination of the relevant fluconazole minimum inhibitory concentrations for heavy trailing Candida isolates with low-high phenotype (2010) Mycoses, 53, pp. 475-480Abi-Said, D., Anaissie, E., Uzun, O., Pinzcowski, H., Vartivarian, S., The epidemiology of hematogenous candidiasis caused by different Candida species (1997) Clin Infect Dis, 24, pp. 1122-1128Nucci, M., Queiroz-Telles, F., Tobón, A.M., Restrepo, A., Colombo, A.L., Epidemiology of opportunistic fungal infections in Latin America (2010) Clin Infect Dis, 51, pp. 561-570Sampaio Camargo, T.Z., Marra, A.R., Silva, C.V., Secular trends of candidemia in a tertiary care hospital (2010) Am J Infect Control, 38, pp. 546-551Pfaller, M.A., Diekema, D.J., Jones, R.N., International surveillance of bloodstream infections due to Candida species: frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole and voriconazole of isolates collected from 1997 through 1999 in the SENT RY antimicrobial surveillance program (2001) J Clin Microbiol, 39, pp. 3254-3259Safran, D.B., Dawson, E., The effect of empiric and prophylactic treatment with fluconazole on yeast isolates in a surgical trauma intensive care unit (1997) Arch Surg, 132, pp. 1184-1188Pfaller, M.A., Messer, S.A., Boyken, L., Tendolkar, S., Hollis, R.J., Diekema, D.J., Geographic variation in the susceptibilities of invasive isolates of Candida glabrata to seven systemically active antifungal agents: a global assessment from the ARTEMIS Antifungal Surveillance Program conducted in 2001 and 2002 (2004) J Clin Microbiol, 42, pp. 3142-3146Diekema, D.J., Pfaller, M.A., Jones, R.N., Age-related trends in pathogen frequency and antimicrobial susceptibility of bloodstream isolates in North America. SENT RY Antimicrobial Surveillance Program, 1997-2000 (2002) Int J Antimicrob Agents, 20, pp. 412-418Iwen, P.C., Kelly, D.M., Reed, E.C., Hinrichs, S.H., Invasive infection due to Candida krusei in immunocompromised patients not treated with fluconazole (1995) Clin Infect Dis, 20, pp. 342-347Drago, M., Scaltrito, M.M., Morace, G., In vitro activity of voriconazole and other antifungal agents against clinical isolates of Candida glabrata and Candida krusei (2004) Eur J Clin Microbiol Infect Dis, 23, pp. 619-624Girmenia, C., Pizzarelli, G., Cristini, F., Candida guilliermondii fungemia in patients with hematologic malignancies (2006) J Clin Microbiol, 44, pp. 2458-2464Hazen, K.C., New and emerging yeast pathogens (1995) Clin Microbiol Rev, 8, pp. 462-478Merz, W.G., Candida lusitaniae: frequency of recovery, colonization, infection and amphotericin B resistance (1984) J Clin Microbiol, 20, pp. 1194-1195Hata, D.J., Hall, L., Fothergill, A.W., Larone, D.H., Wengenack, N.L., Multicenter evaluation of the new VITEK 2 advanced colorimetric yeast identification card (2007) J Clin Microbiol, 45, pp. 1087-1092Forrest, G., Role of antifungal susceptibility testing in patient management (2006) Curr Opin Infect Dis, 19, pp. 538-543Perkhofer, S., Mrazek, C., Hartl, L., Lass-Flörl, C., In vitro susceptibility testing in fungi: what is its role in clinical practice? (2010) Curr Infect Dis Rep, 12, pp. 401-408Traeder, C., Kowoll, S., Arastéh, K., Candida infection in HIV positive patients 1985-2007 (2008) Mycoses, 51 (SUPPL. 2), pp. 58-61(2008) Reference method for broth dilution antifungal susceptibility testing of yeasts. Document M27-A3, 28, pp. 1-7. , Clinical and Laboratory Standards Institute (CLSI)Subcommittee on Antifungal Susceptibility Testing (AFST) of the, ESCMID European Committee for Antimicrobial Susceptibility Testing (EUCAST). EUCAST Definitive Document EDef 7.1: method for the determination of broth dilution MICs of antifungal agents for fermentative yeasts (2008) Clin Microbiol Infect, 14, pp. 398-405Farina, C., Manso, E., Andreoni, S., Interlaboratory evaluation of VITEK-2 system and Sensititre YeastOne® for antifungal susceptibility testing of yeasts isolated from blood cultures against four antifungal agents (2011) New Microbiol, 34, pp. 195-201Cuenca-Estrella, M., Rodriguez-Tudela, J.L., The current role of the reference procedures by CLSI and EUCAST in the detection of resistance to antifungal agents in vitro (2010) Expert Rev Anti Infect Ther, 8, pp. 267-276Baginski, M., Czub, J., Amphotericin B and its new derivatives - mode of action (2009) Curr Drug Metab, 10, pp. 459-469Laniado-Laborín, R., Cabrales-Vargas, M.N., Amphotericin B: side effects and toxicity (2009) Rev Iberoam Micol, 26, pp. 223-227Rüping, M.J., Vehreschild, J.J., Cornely, O.A., Antifungal treatment strategies in high risk patients (2008) Mycoses, 51 (SUPPL. 2), pp. 46-51Wingard, J.R., White, M.H., Anaissie, E., A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study Group (2000) Clin Infect Dis, 31, pp. 1155-1163Safdar, A., Ma, J., Saliba, F., Drug-induced nephrotoxicity caused by amphotericin B lipid complex and liposomal amphotericin B: a review and meta-analysis (2010) Medicine (Baltimore), 89, pp. 236-244Groll, A.H., Walsh, T.J., Uncommon opportunistic fungi: new nosocomial threats (2001) Clin Microbiol Infect, 7 (SUPPL. 2), pp. 8-24Pappas, P.G., Invasive candidiasis (2006) Infect Dis Clin N Am, 20, pp. 485-506Maertens, J.A., History of the development of azole derivatives (2004) Clin Microbiol Infect, 10 (SUPPL. 1), pp. 1-10Como, J.A., Dismukes, W.E., Oral azole drugs as systemic antifungal therapy (1994) N Engl J Med, 330, pp. 263-272Heeres, J., Meerpoel, L., Lewi, P., Conazoles (2010) Molecules, 15, pp. 4129-4188Aperis, G., Mylonakis, E., Newer triazole antifungal agents: pharmacology, spectrum, clinical efficacy and limitations (2006) Expert Opin Invest Drugs, 15, pp. 579-602Pfaller, M.A., Espinel-Ingroff, A., Boyken, L., Comparison of the broth microdilution (BMD) method of the European Committee on Antimicrobial Susceptibility Testing with the 24-hour CLSI BMD method for testing susceptibility of Candida species to fluconazole, posaconazole, and voriconazole by use of epidemiological cutoff values (2011) J Clin Microbiol, 49, pp. 845-850Arendrup, M.C., Epidemiology of invasive candidiasis (2010) Curr Opin Crit Care, 16, pp. 445-452Wheat, J., Sarosi, G., McKinsey, D., Practice guidelines for the management of patients with histoplasmosis. Infectious Diseases Society of America (2000) Clin Infect Dis, 30, pp. 688-695Shikanai-Yasuda, M.A., Telles Filho Fde, Q., Mendes, R.P., Colombo, A.L., Moretti, M.L., Guidelines in paracoccidioidomycosis (2006) Rev Soc Bras Med Trop, 39, pp. 297-310De Sarro, A., La Camera, E., Fera, M.T., New and investigational triazole agents for the treatment of invasive fungal infections (2008) J Chemother, 20, pp. 661-671Charlier, C., Hart, E., Lefort, A., Fluconazole for the management of invasive candidiasis: where do we stand after 15 years? (2006) J Antimicrob Chemother, 57, pp. 384-410Goa, K.L., Barradell, L.B., Fluconazole. An update of its pharmacodynamic and pharmacokinetic properties and therapeutic use in major superficial and systemic mycoses in immunocompromised patients (1995) Drugs, 50, pp. 658-690Scott, L.J., Simpson, D., Voriconazole: a review of its use in the management of invasive fungal infections (2007) Drugs, 67, pp. 269-298Walsh, T.J., Anaissie, E.J., Denning, D.W., Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America (2008) Clin Infect Dis, 46, pp. 327-360Kullberg, B.J., Sobel, J.D., Ruhnke, M., Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomized non-inferiority trial (2005) Lancet, 366, pp. 1435-1442Mehta, A.K., Langston, A.A., Use of posaconazole in the treatment of invasive fungal infections (2009) Expert Rev Hematol, 2, pp. 619-630Sucher, A.J., Chahine, E.B., Balcer, H.E., Echinocandins: the newest class of antifungals (2009) Ann Pharmacother, 43, pp. 1647-1657Hope, W.W., Shoham, S., Walsh, T.J., The pharmacology and clinical use of caspofungin (2007) Expert Opin Drug Metab Toxicol, 3, pp. 263-274Fisher, B.T., Zaoutis, T., Caspofungin for the treatment of pediatric fungal infections (2008) Pediatr Infect Dis J, 27, pp. 1099-1102Garnock-Jones, K.P., Keam, S.J., Caspofungin: in pediatric patients with fungal infections (2009) Paediatr Drugs, 11, pp. 259-269Lehrnbecher, T., Groll, A.H., Micafungin: a brief review of pharmacology, safety, and antifungal efficacy in pediatric patients (2010) Pediatr Blood Cancer, 55, pp. 229-232Menichetti, F., Anidulafungin, a new echinocandin: effectiveness and tolerability (2009) Drugs, 69 (SUPPL. 1), pp. 95-97Pappas, P.G., Rotstein, C.M., Betts, R.F., Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis (2007) Clin Infect Dis, 45, pp. 883-893Temesgen, Z., Barreto, J., Vento, S., Micafungin - the newest echinocandin (2009) Drugs Today (Barc), 45, pp. 469-478The periodic health examination (1979) Can Med Assoc J, 121, pp. 1193-1254. , Canadian Task Force on the Periodic Health ExaminationVazquez, J.A., Sobel, J.D., Mucosal candidiasis (2002) Infect Dis Clin N Am, 16, pp. 793-820Weerasuriya, N., Snape, J., A study of Candida esophagitis in elderly patients attending a district general hospital in the UK (2006) Dis Esophagus, 19, pp. 189-192Sugar, A.M., Oroesophageal candidiasis (2004) AIDS Read, 14, p. 572Vazquez, J.A., Invasive oroesophageal candidiasis: current and developing treatment options (2003) Drugs, 63, pp. 971-989Goldman, M., Cloud, G.A., Wade, K.D., A randomized study of the use of fluconazole in continuous versus episodic therapy in patients with advanced HIV infection and a history of oropharyngeal candidiasis: AIDS Clinical Trials Group Study 323/Mycoses Study Group Study 40 (2005) Clin Infect Dis, 41, pp. 1473-1480Underwood, J.A., Williams, J.W., Keate, R.F., Clinical findings and risk factors for Candida esophagitis in outpatients (2003) Dis Esophagus, 16, pp. 66-69Ellepola, A.N., Samaranayake, L.P., Oral candidal infections and antimycotics (2000) Crit Rev Oral Biol Med, 11, pp. 172-198Golub, J.S., Johns, M.M., Esophageal candidiasis (2005) Ear Nose Throat J, 84, p. 765Cha, R., Sobel, J.D., Fluconazole for the treatment of candidiasis: 15 years experience (2004) Expert Rev Anti Infect Ther, 2, pp. 357-366